NCT05886829View on ClinicalTrials.gov

Chlorpheniramine Nasal Spray to Accelerate COVID-19 Clinical Recovery in an Outpatient Setting: ACCROS-III

PHASE2/PHASE3CompletedINTERVENTIONAL
Enrollment

157

Participants

Timeline

Start Date

July 27, 2022

Primary Completion Date

January 19, 2023

Study Completion Date

February 1, 2023

Conditions
COVID-19Symptoms and SignsCOVID-19 PandemicCoronavirus Disease 2019Coronavirus Infections
Interventions
COMBINATION_PRODUCT

Chlorpheniramine Maleate 0.4% Nasal Spray

Chlorpheniramine Maleate 0.4% Nasal Spray

COMBINATION_PRODUCT

Placebo

Placebo nasal spray

Trial Locations (1)

Unknown

Hospital CEMESA, Cortés

Sponsors
All Listed Sponsors
collaborator

Hospital CEMESA Cortés, San Pedro Sula, Honduras

UNKNOWN

lead

Dr. Ferrer BioPharma

INDUSTRY